For patients with < 3 years since their first symptom , significantly fewer new/newly enlarged T2 lesions were observed with fingolimod versus IFN-1a IM ( mean number , 1.94 vs. 2.95 ; P = 0.036 ) or placebo ( 4.1 vs. 10.7 ; P < 0.001 ) ; the mean number of gadolinium-enhancing T1 lesions was significantly reduced versus placebo ( 0.3 vs. 1.1 ; P < 0.001 ) .